On March 23, Hana Securities stated that the short-term share price of CJ CheilJedang is expected to be more heavily influenced by whether there is an improvement in the bio industry market conditions.


[Click e-Stock] "For CJ CheilJedang, 'Improvement in Bio Market Conditions' Is Key" View original image

Shim Eunju, a researcher at Hana Securities, said in a report released that day, "Bio will inevitably see a significant drop in profit in the first half of the year, and market conditions for major amino acids, including lysine, remain sluggish," adding, "Due to weak pricing for major amino acids and poor demand for nucleic acids, excluding 'Selecta', the amino acid business is expected to post a slight deficit."


CJ CheilJedang's consolidated revenue for the first quarter of this year is expected to decrease by 5.1% to 6.8383 trillion won, with operating profit forecast to fall by 20.5% to 265 billion won. The key determinant for quarterly earnings this year is the bio segment. Last year, the bio division contributed around 100 billion won to first-quarter profit, but this year it is expected to hover around the break-even point. However, in the second half of the year, rising oil prices are expected to put upward pressure on overall grain prices, including soybeans, and the recovery in lysine demand is anticipated due to the rise in pork prices in China. There is also a possibility that demand for nucleic acids will recover along with the Chinese economy.



Researcher Shim added, "At last year's fourth-quarter earnings announcement, management expressed its intention to improve the financial structure through the liquidation of non-core assets. In Korea, the company already has experience selling non-core assets such as the Gayang-dong site and the talent development center in 2019, and this time, it appears likely that asset reallocation will take place not only in Korea but also overseas."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing